Home  |  Contact

UniProtKB/Swiss-Prot Q9UKV8: Variant p.Gly733Arg

Protein argonaute-2
Gene: AGO2
Variant information

Variant position:  733
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Glycine (G) to Arginine (R) at position 733 (G733R, p.Gly733Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In LESKRES; complete loss of function. Changes in the subcellular location pattern. Diffuse location into the cytoplasm. Does not bind mRNA. Abolishes interaction with DICER1. Abolishes phosphorylation of the C-terminal serine cluster. Does not affect phosphorylation of Ser-387.
Any additional useful information about the variant.



Sequence information

Variant position:  733
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  859
The length of the canonical sequence.

Location on the sequence:   TRLFCTDKNERVGKSGNIPA  G TTVDTKITHPTEFDFYLCSH
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         TRLFCTDKNERVGKSGNIPAGTTVDTKITHPTEFDFYLCSH

Mouse                         TRLFCTDKNERVGKSGNIPAGTTVDTKITHPTEFDFYLCSH

Rat                           TRLFCTDKNERVGKSGNIPAGTTVDTKITHPTEFDFYLCSH

Bovine                        TRLFCTDKNERVGKSGNIPAGTTVDTKITHPTEFDFYLCSH

Xenopus laevis                TRLFCTDRNERVGKSGNIPAGTTVDTKITHPSEFDFYLCSH

Xenopus tropicalis            TRLFCTDRNERVGKSGNIPAGTTVDTKITHPSEFDFYLCSH

Drosophila                    TRFFPSGDVTTSNKFNNVDPGTVVDRTIVHPNEMQFFMVSH

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 859 Protein argonaute-2
Domain 517 – 818 Piwi
Alternative sequence 724 – 757 Missing. In isoform 2.
Mutagenesis 744 – 744 T -> Y. No effect.


Literature citations

Germline AGO2 mutations impair RNA interference and human neurological development.
Lessel D.; Zeitler D.M.; Reijnders M.R.F.; Kazantsev A.; Hassani Nia F.; Bartholomaeus A.; Martens V.; Bruckmann A.; Graus V.; McConkie-Rosell A.; McDonald M.; Lozic B.; Tan E.S.; Gerkes E.; Johannsen J.; Denecke J.; Telegrafi A.; Zonneveld-Huijssoon E.; Lemmink H.H.; Cham B.W.M.; Kovacevic T.; Ramsdell L.; Foss K.; Le Duc D.; Mitter D.; Syrbe S.; Merkenschlager A.; Sinnema M.; Panis B.; Lazier J.; Osmond M.; Hartley T.; Mortreux J.; Busa T.; Missirian C.; Prasun P.; Luettgen S.; Mannucci I.; Lessel I.; Schob C.; Kindler S.; Pappas J.; Rabin R.; Willemsen M.; Gardeitchik T.; Loehner K.; Rump P.; Dias K.R.; Evans C.A.; Andrews P.I.; Roscioli T.; Brunner H.G.; Chijiwa C.; Lewis M.E.S.; Jamra R.A.; Dyment D.A.; Boycott K.M.; Stegmann A.P.A.; Kubisch C.; Tan E.C.; Mirzaa G.M.; McWalter K.; Kleefstra T.; Pfundt R.; Ignatova Z.; Meister G.; Kreienkamp H.J.;
Nat. Commun. 11:5797-5797(2020)
Cited for: INVOLVEMENT IN LESKRES; VARIANTS LESKRES CYS-201; VAL-201; GLN-203; MET-357; THR-364; PRO-367; SER-573; ARG-733; TYR-751 AND ARG-760; CHARACTERIZATION OF VARIANTS LESKRES PRO-192; CYS-201; VAL-201; GLN-203; MET-357; THR-364; PRO-367; SER-573; ARG-733; TYR-751 AND ARG-760; SUBCELLULAR LOCATION; PHOSPHORYLATION AT SER-387; INTERACTION WITH DICER1;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.